🚀 VC round data is live in beta, check it out!
Chengdu Kanghua Valuation Multiples
Discover revenue and EBITDA valuation multiples for Chengdu Kanghua and similar public comparables like GH Research, Neuren Pharma, Jade Biosciences, Alvotech and more.
Chengdu Kanghua Overview
About Chengdu Kanghua
Chengdu Kanghua Biological Products Co Ltd is engaged in research, development, production, sales and technical services of biological products for prevention, and the existing products include Group ACYW135 Meningococcal Polysaccharide Vaccine-Maikexin, Rabies Vaccine (human diploid cell) for Human Use, freeze-dried - HDCV. The company's products include ACYW135 Meningococcal Polysaccharide Vaccine; and Rabies Vaccine.
Founded
2004
HQ
Employees
N/A
Website
Sectors
Financials (LTM)
EV
$1B
Chengdu Kanghua Financials
Chengdu Kanghua reported last 12-month revenue of $181M and EBITDA of $61M.
In the same LTM period, Chengdu Kanghua generated $168M in gross profit, $61M in EBITDA, and $35M in net income.
Revenue (LTM)
Chengdu Kanghua P&L
In the most recent fiscal year, Chengdu Kanghua reported revenue of $210M and EBITDA of $79M.
Chengdu Kanghua expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $181M | XXX | $210M | XXX | XXX | XXX |
| Gross Profit | $168M | XXX | $198M | XXX | XXX | XXX |
| Gross Margin | 93% | XXX | 94% | XXX | XXX | XXX |
| EBITDA | $61M | XXX | $79M | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | 38% | XXX | XXX | XXX |
| EBIT Margin | 23% | XXX | 38% | XXX | XXX | XXX |
| Net Profit | $35M | XXX | $58M | XXX | XXX | XXX |
| Net Margin | 19% | XXX | 28% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Chengdu Kanghua Stock Performance
Chengdu Kanghua has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
Chengdu Kanghua's stock price is $8.76.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | 0.8% | XXX | XXX | XXX | $0.45 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialChengdu Kanghua Valuation Multiples
Chengdu Kanghua trades at 5.7x EV/Revenue multiple, and 16.9x EV/EBITDA.
EV / Revenue (LTM)
Chengdu Kanghua Financial Valuation Multiples
As of April 18, 2026, Chengdu Kanghua has market cap of $1B and EV of $1B.
Equity research analysts estimate Chengdu Kanghua's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Chengdu Kanghua has a P/E ratio of 32.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 5.7x | XXX | 4.9x | XXX | XXX | XXX |
| EV/EBITDA | 16.9x | XXX | 13.0x | XXX | XXX | XXX |
| EV/EBIT | 24.2x | XXX | 12.7x | XXX | XXX | XXX |
| EV/Gross Profit | 6.1x | XXX | 5.2x | XXX | XXX | XXX |
| P/E | 32.4x | XXX | 19.5x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 16.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Chengdu Kanghua Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Chengdu Kanghua Margins & Growth Rates
Chengdu Kanghua's revenue in the last 12 month grew by 11%.
Chengdu Kanghua's rule of 40 is 50% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Chengdu Kanghua's rule of X is 68% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Chengdu Kanghua Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | (17%) | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | 38% | XXX | XXX | XXX |
| EBITDA Growth | 31% | XXX | (30%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 50% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 68% | XXX | XXX | XXX |
| S&M Expenses to Revenue | 44% | XXX | 36% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 12% | XXX | 7% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 13% | XXX | 9% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 56% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Chengdu Kanghua Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Chengdu Kanghua | XXX | XXX | XXX | XXX | XXX | XXX |
| GH Research | XXX | XXX | XXX | XXX | XXX | XXX |
| Neuren Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Jade Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Alvotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Aktis Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Chengdu Kanghua M&A Activity
Chengdu Kanghua acquired XXX companies to date.
Last acquisition by Chengdu Kanghua was on XXXXXXXX, XXXXX. Chengdu Kanghua acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Chengdu Kanghua
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialChengdu Kanghua Investment Activity
Chengdu Kanghua invested in XXX companies to date.
Chengdu Kanghua made its latest investment on XXXXXXXX, XXXXX. Chengdu Kanghua invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Chengdu Kanghua
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Chengdu Kanghua
| When was Chengdu Kanghua founded? | Chengdu Kanghua was founded in 2004. |
| Where is Chengdu Kanghua headquartered? | Chengdu Kanghua is headquartered in China. |
| Is Chengdu Kanghua publicly listed? | Yes, Chengdu Kanghua is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Chengdu Kanghua? | Chengdu Kanghua trades under 300841 ticker. |
| When did Chengdu Kanghua go public? | Chengdu Kanghua went public in 2020. |
| Who are competitors of Chengdu Kanghua? | Chengdu Kanghua main competitors are GH Research, Neuren Pharma, Jade Biosciences, Alvotech. |
| What is the current market cap of Chengdu Kanghua? | Chengdu Kanghua's current market cap is $1B. |
| What is the current revenue of Chengdu Kanghua? | Chengdu Kanghua's last 12 months revenue is $181M. |
| What is the current revenue growth of Chengdu Kanghua? | Chengdu Kanghua revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Chengdu Kanghua? | Current revenue multiple of Chengdu Kanghua is 5.7x. |
| Is Chengdu Kanghua profitable? | Yes, Chengdu Kanghua is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Chengdu Kanghua? | Chengdu Kanghua's last 12 months EBITDA is $61M. |
| What is Chengdu Kanghua's EBITDA margin? | Chengdu Kanghua's last 12 months EBITDA margin is 34%. |
| What is the current EV/EBITDA multiple of Chengdu Kanghua? | Current EBITDA multiple of Chengdu Kanghua is 16.9x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.